Immune Reconstitution Hepatitis in HIV and Hepatitis B Coinfection, Despite Lamivudine Therapy as Part of HAART

Drake, Anne; Mijch, Anne; Sasadeusz, Joe
July 2004
Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p129
Academic Journal
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection occurs commonly. The introduction of antiretroviral therapy can result in immune reconstitution hepatitis. We describe 2 coinfected patients who developed clinical flares of HBV disease, despite the inclusion of lamivudine, a drug with anti-HBV activity, in their HAART regimens. Potential strategies to manage individuals with HBV/HIV coinfection are discussed.


Related Articles

  • Antiretroviral Therapy for Hepatitis B Virus--HIV--Coinfected Patients: Promises and Pitfalls. Levy, Vivian; Grant, Robert M. // Clinical Infectious Diseases;10/1/2006, Vol. 43 Issue 7, p904 

    Coinfections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally. HIV infection modifies the course of HBV infection by increasing rates of chronicity, prolonging HBV viremia, and increasing liver-related morbidity. To minimize the emergence of HIV and/or HBV...

  • Effect of HIV Infection and Antiretroviral Therapy on Hepatitis B Virus (HBV)--Specific T Cell Responses in Patients Who Have Resolved HBV Infection. Lascar, R. Monica; Lopes, A. Ross; Gilson, Richard J.; Dunn, Claire; Johnstone, Ruth; Copas, Andrew; Reignat, Stephanie; Webster, George; Bertoletti, Antonio; Maini, Mala K. // Journal of Infectious Diseases;4/1/2005, Vol. 191 Issue 7, p1169 

    Coinfection with hepatitis B virus (HBV) is a common occurrence in human immunodeficiency virus (HIV)- positive patients and an increasing cause of morbidity and mortality. The CD8+ T cell response is critical for long-term control of HBV in patients resolving acute infection. Here, we examine...

  • An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly. Stray, Stephen J.; Johnson, Jennifer M.; Kopek, Benjamin G.; Zlotnick, Adam // Nature Biotechnology;Mar2006, Vol. 24 Issue 3, p358 

    Virus assembly has not been routinely targeted in the development of antiviral drugs, in part because of the lack of tractable methods for screening in vitro. We have developed an in vitro assay of hepatitis B virus (HBV) capsid assembly, based on fluorescence quenching of dye-labeled capsid...

  • New insights into hepatitis B virus biology and implications for novel antiviral strategies. Yaming Li; Lu Bai; Jieliang Chen; Wen Zhang; Kuancheng Liu; Zhenghong Yuan; Min Wu; Xiaohui Zhou // National Science Review;2015, Vol. 2 Issue 3, p296 

    Hepatitis B virus (HBV), a small DNA virus with a unique replication mode, can cause chronic hepatitis (CHB), which is characterized by the persistence of the viral covalently closed circular DNA that serves as the template for HBV replication and the production of large amounts of secreted HBV...

  • Dual Efficacy of Lamivudine Treatment in Human Immunodeficiency Virus/Hepatitis B... Dore, Gregory J.; Cooper, David A.; Barrett, Catherine; Li-Ean Goh; Thakrar, Bharat; Atkins, Mark // Journal of Infectious Diseases;9/1/99, Vol. 180 Issue 3, p607 

    Examines the efficacy and safety of lamivudine in persons coinfected with HIV type 1 and hepatitis B virus (HBV) using a coinfected persons in a randomized, controlled study. Drugs added to lamivudine under the treatment process used in the study; Effect of coinfection with HIV type 1 on HBV...

  • Hepatitis B Virus Drug Resistance in HIV-1–Infected Patients Taking Lamivudine-Containing Antiretroviral Therapy. Wongprasit, Pawinee; Manosuthi, Weerawat; Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek // AIDS Patient Care & STDs;Apr2010, Vol. 24 Issue 4, p205 

    A cross-sectional study was conducted in HIV-1–infected patients receiving lamivudine-containing antiretroviral therapy (ART) to determine the prevalence and risk factors of hepatitis B virus drug resistance (HBV-DR). HBV DNA and HBV genotypic resistance test were performed. Patients were...

  • Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan. Masaadeh, Hani A.; Hayajneh, Wail A.; Alqudah, Enayat A.; Gretch, David R.; Sun-Lung Tsai // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7231 

    AIM: To investigate and identify prevalent hepatitis B virus (HBV) genotypes and to explore lamivudine-resistant mutations among treated and untreated patients in Jordan. METHODS: A total of 107 cases with chronic hepatitis B were recruited from different medical centers in Jordan. Serological...

  • Emtricitabine/Tenofovir Disoproxil Fumarate. Adis International Limited // Drugs in R&D;2004, Vol. 5 Issue 3, p160 

    Gilead Sciences is developing a fixed-dose co-formulation of two of its reverse transcriptase inhibitors, emtricitabine [Emtriva™] and tenofovir disoproxil fumarate [Viread®], for once-daily dosing in combination with other antiretrovirals for the treatment of HIV infection. Each...

  • Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. Gatanaga, Hiroyuki; Hayashida, Tsunefusa; Tanuma, Junko; Oka, Shinichi // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 12, p1812 

    Serological analysis of stocked serum samples showed lower incidence of hepatitis B virus (HBV) infection in non-HBV-vaccinated human immunodeficiency virus–infected men who have sex with men on lamivudine- or tenofovir disoproxil fumarate–based antiretroviral therapy.Background....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics